SS Innovations International (SSII) has received approval to uplist from OTC to Nasdaq Capital Market, with trading set to commence on April 25, 2025, under the same ticker 'SSII'. The company, focused on affordable surgical robotic technologies, reported significant achievements with its SSi Mantra surgical robotic system:
Key highlights include:Installation of 80 systems across 75 hospitals in India and other countries
3,500+ successful surgeries, including 195+ cardiac procedures with zero device-related complications
First Indian company to receive CDSCO approval for telesurgery
Completed 16 telesurgeries, including world's first robotic cardiac telesurgeries at distances up to 1,200 miles
The company reported strong financial performance with revenue of $20.6 million for 2024, a 251% increase from 2023's $5.9 million, and improved gross margin from 12.3% to 40.9%. SSII is pursuing EU CE Mark and U.S. FDA approval, expected in late 2025 and early 2026, respectively.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.